• Skip to primary navigation
  • Skip to main content
  • Skip to footer
  • LinkedIn
  • YouTube
  • Instagram
  • X
  • Contact Us
  • Clinical Trials
  • Careers
  • Investors
Insmed Insmed

Insmed

  • Company

    Company

    Get to know Insmed, see what drives us, and learn how we’re building a company where people come first.

    Learn about our company

    • Culture
    • What Guides Us
    • Management Team
    • Board of Directors
    • Partnerships

    Our Global Company

    Find available career opportunities in the U.S., Japan, or Europe.

    Find Jobs

  • Patients

    Patients

    See how we collaborate with patients to shape every step of our shared journey.

    Learn about our
    commitment to patients

    • Disease Areas
    • Patient Advocacy & Resources
    • Patient Access

    Current Clinical Trials

    Learn more about our clinical trials or find a relevant trial near you.

    See if you may qualify

  • Science

    Science

    Discover the innovative science that fuels our commitment to delivering breakthroughs.

    Learn about our science

    • Pipeline
    • Areas of Innovation
      • Gene Therapy with Targeted Delivery
      • Protein Deimmunization
      • RNA End-Joining
      • Synthetic Rescue
    • Investigator-Initiated Research
    • Grants & Funding
  • Therapies

    Therapies

    Learn about our therapies

    • ARIKAYCE®
    • BRINSUPRI®
  • Responsibility

    Responsibility

    See how we’re continuing to advance science sustainably and ethically.

    Learn about our
    commitment to responsibility

    • Patients we serve
    • Innovation we deliver
    • People we empower
    • Communities we strengthen
    • Planet we protect
    • Governance we uphold
      • Global Healthcare Compliance
      • Policies & Disclosures

    Responsibility Report

    Our Responsibility Report reflects the culture and purpose we live by every day. We are committed to reporting annually on our progress and commitments.

    Learn more

  • Company
    • Company
    • Culture
    • What Guides Us
    • Management Team
    • Board of Directors
    • Partnerships
  • Patients
    • Patients
    • Disease Areas
    • Patient Advocacy & Resources
    • Patient Access
  • Science
    • Science
    • Pipeline
    • Areas of Innovation
      • Gene Therapy with Targeted Delivery
      • Protein Deimmunization
      • RNA End-Joining
      • Synthetic Rescue
    • Investigator-Initiated Research
    • Grants & Funding
  • Therapies
    • Therapies
    • ARIKAYCE®
      BRINSUPRI®
  • Responsibility
    • Responsibility
    • Patients we serve
    • Innovation we deliver
    • People we empower
    • Communities we strengthen
    • Planet we protect
    • Governance we uphold
    • Global Healthcare Compliance
    • Policies & Disclosures
  • Investors
  • Press Releases
  • Events & Presentations
  • Financials & Filings
    • Earnings Results
    • Annual Reports
    • SEC Filings
  • Corporate Governance
  • Responsibility Reports
  • Resources
    • Stock Information
    • Investor FAQs
    • Analyst Coverage
    • Email Alerts

Press Releases

Month Year
Su Mo Tu We Th Fr Sa
Month Year
Su Mo Tu We Th Fr Sa
Email Alerts
Advanced Search
  
Asset Types
           
 Basic Search
  • Oct 24, 2011
    Insmed Incorporated Provides Regulatory Update on ARIKACE® in Non-Tuberculous Mycobacteria Indication

    Read more

  • Oct 10, 2011
    Insmed Incorporated Provides Regulatory Update

    Read more

  • Sep 26, 2011
    Insmed to Present at Sixth Annual JMP Securities Healthcare Conference

    Read more

  • Aug 11, 2011
    Insmed to Present at 2011 Wedbush Securities Life Sciences Management Access Conference

    Read more

  • Aug 8, 2011
    Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011

    Read more

  • Aug 1, 2011
    Insmed Incorporated Announces Clinical Hold on ARIKACE® Phase 3 Clinical Trials

    Read more

  • Jul 26, 2011
    Insmed to Host 2011 Second Quarter Earnings Conference Call

    Read more

  • Jul 18, 2011
    Andrea Drucker Joins Insmed as General Counsel

    Read more

  • Jun 28, 2011
    Insmed Announces its Addition to the Russell 3000® Index

    Read more

  • Jun 10, 2011
    Insmed's ARIKACE® Demonstrates Sustained Benefit Through Six Cycles of Treatment for Cystic Fibrosis Patients With Pseudomonas Lung Infections

    Read more

Show 5102550100 per page
  • «
  • 1
  • …
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • …
  • 78
  • »
Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your email alerts.

Sign Up

Investor Presentation

View the latest Insmed Investor Presentation

Download

Footer

Insmed

LinkedIn YouTube Instagram X

Terms of Use Privacy Policy California Notice at Collection U.S. Consumer Health Data Privacy Policy Your Privacy Choices

© 2026 Insmed Incorporated. All Rights Reserved.

You are now leaving Insmed's website.

Insmed does not control, review, or endorse third-party websites, and you agree that Insmed is not responsible for the content of the website you are about to enter.